glenzocimab

WITHDRAWN · PHASE2, PHASE3 · Acute Ischemic Stroke

The study was discontinued following the cessation of the company's activities, which resulted in the investigational medicinal product no longer being available.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.